Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

4.300 +0.420 (+10.82%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
More People are Microdosing Psychedelics to Ease the Challenges of Parenting
Via Investor Brand Network
Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression
From Compass Pathways plc
Via Business Wire
Compass Pathways to Participate in Stifel Virtual CNS Forum
From Compass Pathways plc
Via Business Wire
Earnings Scheduled For February 27, 2025
Via Benzinga
US Embassy Tells Americans to Desist from Using Ayahuasca in Peru
Via Investor Brand Network
Topics Law Enforcement
Mind Medicine's Net Losses Swell In Q4, But Retail Finds At Least 3 Reasons To Stay Bullish
The psychedelics treatment developer reported a net loss of $34.7 million for the quarter ended Dec. 31, 2024, widening from a $23.8 million loss a year earlier. 
Via Stocktwits
Psychedelics-Focused Compass Pathways Has Established Itself As 'Credible CNS Biotechnology Company,' Analyst Says
Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026. 
Via Benzinga
Compass Pathways Plc (CMPS) Q4 2024 Earnings Call Transcript
CMPS earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
This Plumas Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday
Via Benzinga
Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights
From Compass Pathways plc
Via Business Wire
Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference
From Compass Pathways plc
Via Business Wire
Washington State Bills Seek to Legalize Psychedelics for Therapeutic Use
Via Investor Brand Network
Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025
From Compass Pathways plc
Via Business Wire
Mind Medicine Getting An 'RFK Bump'? Retail Gets More Bullish As Stock Heads For Best Day In Over 10 Months
Kennedy has previously advocated for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca. 
Via Stocktwits
RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care.
The Senate will vote Thursday on whether to put RFK Jr. in charge of health. It's unclear how he will impact biotech stocks. 
Via Investor's Business Daily
Compass Pathways to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Compass Pathways plc
Via Business Wire
Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer
From Compass Pathways plc
Via Business Wire
Compass Pathways Announces Pricing of Underwritten Offering
From Compass Pathways plc
Via Business Wire
Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)
From Compass Pathways plc
Via Business Wire
Is Your Mind Ready to Consider Investing in Psychedelics Stocks?
Don't jump in without doing some research first. 
Via The Motley Fool
Compass Pathways to Participate in December Investor Conferences
From Compass Pathways plc
Via Business Wire
COMPASS Pathways: Institutional Pressure Amid $43M Market Cap Decline, What's Next For This Psychedelics Co?
COMPASS Pathways faces $43M market cap loss, raising concerns among institutional investors holding 30% ownership. 
Via Benzinga
Despegar.com, Zai Lab, Bloom Energy And Other Big Stocks Moving Higher On Friday
Via Benzinga
Pfizer, Moderna, Novavax Take A Beating After Trump Taps Kennedy To Head Up HHS
President-elect Donald Trump tapped widely known vaccine skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services. 
Via Investor's Business Daily
Topics Government
FDA Endorses CaaMTech's Psilocin Drug Development For Depression Treatment
FDA supports CaaMTech's CT-4201 psilocin program for depression, advancing psychedelic therapy and clearing key regulatory hurdles. 
Via Benzinga
AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care?
AI and psychedelic medicine are merging, with research showing AI's role in drug discovery, trials, and personalized mental health care. 
Via Benzinga
Topics Artificial Intelligence
Top 3 Health Care Stocks You'll Regret Missing In November
Via Benzinga
Compass Pathways Plc (CMPS) Q3 2024 Earnings Call Transcript
CMPS earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Nasdaq Down 500 Points; Uber Shares Dip After Q3 Results
Via Benzinga
As Psilocybin Trials Face Delays, Compass Pathways (CMPS) Cuts Workforce To Conserve Cash
Compass Pathways delays key Phase 3 psilocybin trial readouts, triggering a 30% workforce reduction amid efforts to conserve cash and refocus. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.